Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concizumab Prophylaxis in Haemophilia A and B Patients With Inhibitors
NCT03196284Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of concizumab in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Annualized Bleeding Rate at 24 weeks. Started Aug 2017; status: completed.
02
Drugs
concizumab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03196284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196284.